Success Metrics

Clinical Success Rate
100.0%

Based on 15 completed trials

Completion Rate
100%(15/15)
Active Trials
4(21%)
Results Posted
33%(5 trials)

Phase Distribution

Ph phase_4
3
16%
Ph phase_2
3
16%
Ph not_applicable
1
5%
Ph phase_1
5
26%
Ph phase_3
7
37%

Phase Distribution

5

Early Stage

3

Mid Stage

10

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
5(26.3%)
Phase 2Efficacy & side effects
3(15.8%)
Phase 3Large-scale testing
7(36.8%)
Phase 4Post-market surveillance
3(15.8%)
N/ANon-phased studies
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

15 of 15 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

19

all time

Status Distribution
Active(4)
Completed(15)

Detailed Status

Completed15
Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (26.3%)
Phase 23 (15.8%)
Phase 37 (36.8%)
Phase 43 (15.8%)
N/A1 (5.3%)

Trials by Status

recruiting316%
completed1579%
active_not_recruiting15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT05014646Phase 2

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Active Not Recruiting
NCT06454383Phase 1

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Recruiting
NCT06141473Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting
NCT05443425Phase 1

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Recruiting
NCT05894928Phase 1

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

Completed
NCT03510884Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed
NCT03510715Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Completed
NCT02890992Phase 2

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed
NCT02249897Phase 4

PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs

Completed
NCT00000463Phase 3

Post Coronary Artery Bypass Graft (CABG) Study

Completed
NCT00000488Phase 3

Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)

Completed
NCT00000461Phase 2

Harvard Atherosclerosis Reversibility Project (HARP)

Completed
NCT01863888Phase 3

Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis

Completed
NCT02046629Phase 1

A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers

Completed
NCT00000594Phase 3

NHLBI Type II Coronary Intervention Study

Completed
NCT01239459Phase 1

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

Completed
NCT01062269Phase 4

A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study

Completed
NCT01122108Phase 4

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

Completed
NCT00677469Not Applicable

Low Doses of Cholestyramine in the Treatment of Hyperthyroidism

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19